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innovation provides opportunities for immediate benefit, including survival until 
the next therapy is available, and may uncover new clinical pathways with signifi-
cant cumulative benefit. Recognition of this “option value” for future health and 
research advances is needed.
PCN295
Use of QUality of Care (QoC) MetriCs aMoNg oNCologists iN the 
UNited states (Us)
Narayanan S, Hautamaki E
Ipsos Healthcare, Washington, DC, USA
Objectives: The 2014 American Society of Clinical Oncology (ASCO) payment 
reform proposal includes value-based adjustments based on performance on qual-
ity, use of/adherence to pathways, and utilization of other healthcare resources. 
The objective of this analysis was to assess current use of QOC metrics in US can-
cer care. MethOds: Medical-oncologists and hematologist/oncologists across the 
US, practicing for at least 2yrs and managing at least 20 patients, were randomly 
sampled to participate in a cross-sectional survey via a panel. Results: 231 phy-
sicians participated (87% physicians, 13% medical directors; 67.5% hematologist/
oncologists, 32.5% medical-oncologists; median age group 40-49yrs). Mean practice 
duration:15yrs; 53% practice in an academic/community/Veteran’s facility and 47% 
in group/solo private practice; 41% are part of an Accountable Care Organization 
(ACO); 89% use electronic health records (EHR). The most common QOC metric 
used was patient satisfaction scores (60%), followed by Quality Oncology Practice 
Initiatives:43%, adherence to clinical pathways:36%, Physician Quality Reporting 
System:35%, Commission on Cancer standards:24%, other:11%, and CancerLinQ:3%; 
None/not-sure:13%. Overall, 81% stated that their organization’s quality measure-
ment and tracking procedures were “somewhat/highly effective” in terms of improv-
ing quality of care, outcomes, and cost-savings. Average of 76% of cancer patients 
were reported to generally adhere to NCCN guidelines/pathways in the organization; 
84% were reported to have documented clinical/pathologic staging prior to initia-
tion of treatment (87% among non-ACO physicians, 80% among ACO physicians; 
p= 0.04). Use of at least one quality metric was more common among physicians 
participating in an ACO (93% vs. 83%; p= 0.04). Use of patient satisfaction scores was 
more common among physicians using EHR (62% vs. 42%; p= 0.048). cOnclusiOns: 
Standard QOC metrics for cancer care appear to be underutilized and appear to vary 
based on an affiliation with an ACO or use of EHR. Impact of observed patterns on 
patient care delivery/outcomes warrants scrutiny.
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Objectives: The Prostate Cancer Registry (NCT02236637) is an international, pro-
spective, observational study of mCRPC patients. One purpose is to evaluate the 
impact of mCRPC treatment on MRU in routine practice. MethOds: Patients were 
enrolled upon initiation of mCRPC treatment or during surveillance in > 150 centres 
across 16 countries. Baseline MRU was collected for 1 year before enrolment, and 
then prospectively at 3-month intervals. Baseline data were converted to a 3-month 
average to align with prospectively-collected data. We analyzed the MRU parameters 
of outpatient visits and hospitalization days at three months after treatment ini-
tiation. Results: We report data from 505 patients who were post-chemotherapy 
(n= 209) or chemotherapy-naïve (n= 296), with mean age 71.5 years and mean time 
since diagnosis 5.7 years. At baseline, MRU was greater for post-chemotherapy vs 
chemotherapy-naïve patients; mean total outpatient visits: 4.8 (range: 0-18) vs 2.5 
(range: 0-13) and mean total hospitalization days: 1.1 (range: 0-15) vs 0.6 (range: 0-8). 
For patients initiating new post-chemotherapy mCRPC treatment during follow-up 
(164/505 patients; 33%), MRU was analyzed by first treatment: abiraterone (n= 74), 
enzalutamide (n= 46), cabazitaxel (n= 44). In the first three months, mean (SD) and 
median [range] number of outpatient visits among patients with evaluable data 
were 4.2 (2.96) and 4.0 [0-13] for abiraterone (n= 51 patients with evaluable data); 
4.3 (2.94) and 4.2 [0-14] for enzalutamide (n= 32); and 7.6 (5.15) and 6.5 [1-30] for 
cabazitaxel (n= 38). During the same period, the mean (SD) number of hospitalization 
days was 2.6 (8.47) for abiraterone (n= 55); 2.2 (5.51) for enzalutamide (n= 33); and 1.5 
(3.94) for cabazitaxel (n= 40). Median number of hospitalization days was zero across 
treatments indicating < 50% of patients required hospitalization. cOnclusiOns: 
As these real-world data mature, the impact of different routine mCRPC treatments 
on MRU across multiple countries, medical disciplines and clinical settings may 
provide valuable insights to benefit patient care.
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Objectives: Radiation oncology is a key therapeutic strategy in cancer care. In 
order to assess the gap between the actual use of this therapy and evidence-based 
indications, we compare the number of new cancer patients that will require at 
least one course of radiotherapy in 24 European countries to its actual use, and 
project the results to 2020. MethOds: Incidence from each cancer type estimated 
by the European Cancer Observatory for 2012 was used in combination with the 
stages at diagnosis from five population-based cancer registries. Projections of can-
cer incidence to 2020 were also used. These data were applied to evidence-based 
decision trees for all tumors to calculate the Optimal Utilization Proportion (OUP). 
Data on actual use come from national radiotherapy societies. Results: Average 
OUP in European countries was 51% with a range from 47% (Russian Federation) 
to 53% (Belgium). The median actual use of radiotherapy was 69% of the OUP in 
the 24 countries analyzed. Only four countries showed an actual use higher than 
80% of the OUP. Projection of cancer incidence to 2020 showed a 10.1% increase in 
the number of candidates for radiotherapy compared to 2012, with most western 
European countries with increases between 10 and 15%. In absolute number of 
patients, this means an increase of 154294 for the EU 27 countries in this 8 years 
period. cOnclusiOns: The gap between optimal and actual use of radiotherapy 
poses a challenge to policy makers when planning future therapeutic resources. 
In order to reduce the gap, the focus on accessibility, reimbursement policies and 
multidisciplinary team clinical decision-making is mandatory. Also, there is a need 
to set reasonable targets that help pave the way to optimal use, keeping in mind the 
challenges which might make the OUP difficult to achieve.
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Objectives: Most policy decisions have a spatial component that can be integrated 
in formal decision making using geographic information systems (GIS) and multi-
criteria decision analysis (MCDA). However, GIS-MCDA is not commonly used in 
a health (economic) policy setting. The aim of this study is to introduce the spa-
tial component of healthcare policy decisions and to illustrate an application of 
GIS-MCDA using a case on comparing lung cancer screening versus smoking preven-
tion programs in the Netherlands. MethOds: Demographic data and data concern-
ing the distribution of persons at-risk of developing lung cancer were obtained from 
the Statistics Netherlands institute and aggregated per public health service (GGD) 
region. Effectiveness and costs data were obtained from literature and assumed to 
differ across population subgroups. The simple multi-attribute rating technique 
(SMART) method of MCDA was used. The GIS-MCDA model was built using ArcGIS 
software. Results: The effectiveness of either a screening or a prevention pro-
gram differed substantially across the GGD regions, reflecting differences in age 
distribution and percentage of young and old smokers. Considering the adjacency 
of regions, a different policy may be optimal for the north-east region (preven-
tion) and the south-west region (screening), but this may raise ethical questions of 
equity. Sensitivity analyses reveal that the decision is sensitive to the percentage 
of older smokers in a region and the relative cost of screening versus prevention. 
Limitations of the study are that the costs of implementation are not taken into 
account, that the time horizon was limited and that a non-exhaustive set of criteria 
was used. cOnclusiOns: GIS-MCDA can be a useful method to gain insight into 
the spatial component of healthcare policy decisions. Further research is required 
into including elicited preference data into the model, into including uncertainty 
in model parameters more formally and into selecting sets of alternatives (e.g. 
screening locations) based on a GIS-MCDA analysis.
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Objectives: Breakthrough innovation in oncology is commonly considered to be 
a substantial increase in overall survival (OS) above specific thresholds. However, 
this growing emphasis on significant OS gain, undervalues new products and may 
not capture aspects of treatment that are important to patients, including qual-
ity of life, delayed progression or improvements in side-effect profiles. We argue 
that progressive innovation in clinical and non-clinical domains needs to be con-
sidered and valued in regulatory and health technology assessment (HTA) deci-
sions. MethOds: Definitions of innovation used in regulatory, HTA, and industry 
were reviewed in the academic and gray literature and current/proposed OS thresh-
olds applied to therapies in colorectal cancer (CRC) and non-small cell lung cancer 
(NSCLC). Results: Regulators and HTA agencies do not provide clear consistent 
definitions of innovation; however, the magnitude of OS benefit is a consistent key 
aspect from both policy (e.g., England’s Cancer Drugs Fund) and clinical perspec-
tives (e.g., ASCO). Emphasis is on “clinically meaningful” change expressed as mini-
mum thresholds: OS gain > 2.5months; HR > 0.8; PFS gain > 3 months, HR > 0.5.. Only 
one of six CRC drugs approved since 2000 met these thresholds (ASCO; Ellis et al. 
2014) although survival has doubled in that time. No NSCLC products have met the 
threshold since 2005 whereas survival in first line treatment for advanced disease 
has doubled. cOnclusiOns: Innovation should be judged in relation to the value 
provided to patients and health systems, and should not be restricted to one-time 
large survival gains. Smaller sequential clinical gains and improved quality of life, 
safety, convenience, and system efficiency should also be considered. Progressive 
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of breast cancer with BMs was derived assuming a steady state approach (with 
incidence equivalent to mortality of metastatic disease), and the average sur-
vival for metastatic breast cancer patients from published literature. Annual SRE 
rates from a European observational retrospective study and the treatment effect 
observed in a head-to-head clinical trial of denosumab versus zoledronic acid 
were used to estimate the total number of predicted SREs by treatment option. 
Country-specific findings from two retrospective studies were used to estimate 
the total number of hospitalisations, inpatient days and direct medical costs 
associated with the management of SREs. Results: Across all countries, the 
estimated prevalence of breast cancer patients with BMs was 87,592 patients: 
Austria, 3,253; Czech Republic, 3,509; Germany, 37,895; Greece, 4,639; Italy, 27,767; 
Spain, 7,553; and Switzerland, 2,975. When denosumab was the selected treat-
ment option, 36,324 SREs were estimated to be avoided per year compared with 
the use of zoledronic acid, which would save 24,110 hospitalisations, 536,551 
inpatient days and 206,605,754€ of direct medical costs (2014 costs in € : Austria, 
23,890,554; Czech Republic, 5,779,856; Germany, 60,659,628; Greece, 15,941,728; 
Italy, 39,998,970; Spain, 17,249,548; and Switzerland, 43,085,469). cOnclusiOns: 
Denosumab’s clinical superiority in the prevention of SREs over zoledronic acid 
could result in significant savings in the number and duration of hospitalisa-
tions, reducing direct medical costs associated with the management of SREs in 
Europe.
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Objectives: In the UK, PCa is the second most common male cancer resulting in 
over 10,000 deaths annually. LHRH agonists (LHRHa), a type of androgen depriva-
tion therapy, are used to help control PCa and delay progression. LHRHa injections 
are available as 1-, 3- and 6-monthly formulations. Triptorelin is the only LHRHa in 
the UK available as a 6-monthly formulation. DESERVE aimed to collect RWE about 
clinical and practical outcomes for patients starting on, or switching to, 6-monthly 
triptorelin. MethOds: A customised data collection programme was designed 
including up to 2 years of data entered retrospectively by physicians from patient 
records at three UK hospitals and prospectively updated over a 5-month period. 
All patients on 6-monthly triptorelin were eligible for entry. The primary outcome 
measure was change in the number of patient–NHS interactions (patient reviews, 
PSA tests and LHRHa injections). Results: 115 patient records were entered; 
records for 88 patients had complete data and were included in the analysis. 47 
were newly diagnosed and initiated on 6-monthly triptorelin; 41 were switched 
from any 3-monthly LHRHa to 6-monthly triptorelin. For switch patients, there was 
a statistically significant reduction in the number of reviews (by 48.4%; p< 0.0001), 
injections (48.4%; p< 0.0001) and PSA tests (29.8%; p< 0.0001) in the 12 months 
following switch versus 12 months before. The total number of patient–NHS inter-
actions was significantly reduced (43.5%; p< 0.0001). At 12 months, median PSA 
was 1.30 ng/mL (23.50 ng/mL at diagnosis) for newly treated patients and 0.24 
ng/mL (0.35 ng/mL at switch) for switch patients. No safety issues were identi-
fied. cOnclusiOns: Patient–NHS interactions were significantly reduced and 
PSA control was maintained with 6-monthly triptorelin vs any 3-monthly LHRHa, 
which translates into NHS savings and improvement in the overall patient experi-
ence. Use of 6-monthly triptorelin may therefore offer advantages over 3-monthly 
formulations for patients, prescribers and payors.
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Objectives: To provide a scientific basis for the clinical use of drugs and the devel-
opment of government drug policy through pharmacoeconomic study of rituximab 
combined with conventional chemotherapy in treating patients with diffuse large 
B-cell lymphoma. MethOds: From the perspective of the health care system, with 
60 years older diffuse large B-cell lymphoma patients in this study, the three-month 
cycle Markov models was established with the time limit of five years and 30 years. 
By controlling treatment, the total direct medical costs of each health status in three 
months associated with DLBCL was got through expert advice and the methods 
Price*Number. The transfer probability between the health statues was calculated 
through survival data of clinical trial; health outcomes within three months of DLBCL 
patients were obtained from literature. On this basis, the pharmacoeconomics eval-
uation was conducted of two programs of rituximab combined with conventional 
chemotherapy and conventional chemotherapy in treating DLBCL. Results: The 
basic analysis showed that: model runs for 5 years, R-CHOP group is more effec-
tive than CHOP group (2.55QALYs> 1.90QALYs), with the higher cost than CHOP 
group (612564.37yuan> 138212.22yuan), the incremental cost-effectiveness ratio 
is 735297.10yuan/QALY.Model runs for 30 years, R-CHOP group is more effec-
tive than CHOP group (4.14QALYs> 2.51QALYs), with the higher cost than CHOP 
group (887550.16yuan> 221662.73yuan), the incremental cost-effectiveness ratio 
is 407808.50yuan/QALY. According to the willingness to pay range (48857.55yuan-
146572.7yuan) which was set by China’s per capita GDP, R-CHOP program has higher 
cost and better effect, but does not have cost-effectiveness advantage in five or 
thirty years. cOnclusiOns: Based on the research’s results and China’s current 
situation, we can say that rituximab combined with conventional chemotherapy 
for DLBCL patients compared with single conventional scheme does not have the 
cost-effectiveness advantage in 5 or 30 years.
Objectives: Thromboembolic (TE) events are a major complication of polycythemia 
vera (PV). Little is known about economic implications of TE events in such patients. 
This study aims to assess the incremental health care resource use (HCRU) and 
costs associated with PV and post-PV TE events in a real-world patient popula-
tion. MethOds: We conducted a retrospective cohort study of PV patients aged < 65 
years enrolled in employer-sponsored commercial health plans in the US. Annual 
all-cause and PV-related HCRU and costs (adjusted to 2014 US dollars) among PV 
patients were compared against non-PV comparison subjects who were propen-
sity-matched on demographics and comorbidities. For patients with a post-PV TE 
event, average 12-month costs following index TE event were assessed. Costs were 
also analyzed in a subgroup receiving hydroxyurea treatment. Results: A total 
of 12,990 PV patients (diagnosed 2000-2012) were included. HCRU was generally 
higher among PV patients versus matched comparison subjects, with largest dif-
ference observed for outpatient hospital visits (90% vs. 70% respectively, p < 0.0001). 
Mean all-cause annual total costs among PV patients were significantly greater 
than comparison subjects ($17,418 vs. $10,501, P < 0.0001). In a subset of patients 
treated with hydroxyurea (n= 774), mean PV-related annual total costs ($7,657) were 
nearly 3 times higher in contrast to costs observed among all PV patients ($2,535). 
Among PV patients experiencing TE events, mean 12-month all-cause costs were 
more than 4 times higher than among those with no TE event ($48,211 vs. $10,958, 
P < 0.0001). cOnclusiOns: Total all-cause HCRU and costs in PV patients were 
substantially higher compared to a matched non-PV comparison group. Patients 
receiving hydroxyurea had higher costs, potentially reflective of inherently more 
severe disease in this patient subgroup. Costs were also substantially higher among 
patients experiencing post-PV TE events, highlighting the importance of treatments 
that may reduce cardiovascular complications in patients with PV.
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Objectives: To estimate the total number of skeletal-related events (SREs), the 
associated hospital burden and direct medical costs when denosumab is used 
instead of zoledronic acid in patients with prostate cancer (PC) and bone metasta-
ses (BMs). MethOds: A model was developed using the following data: country-
specific PC mortality data from the World Health Organization or local registries; 
the proportion of PC patients with BMs from published literature; the prevalence 
of BMs in the metastatic PC population assuming a steady state approach (with 
mortality of metastatic disease equivalent to incidence); and the average survival 
of metastatic PC patients from published literature. Both the annual SREs rates 
from a European observational study and the treatment effect of denosumab 
versus zoledronic acid reported in a head-to-head clinical trial were used to 
predict the total number of SREs by treatment. Country-specific data from two 
multi-country observational studies were used to estimate the total number of 
hospitalisations, length of inpatient stays and direct medical costs associated with 
the management of SREs. Results: Of the 67,375 patients with PC and BMs, the 
prevalence by country was: Austria, 2,447; Czech Republic, 2,707; Germany, 28,447; 
Greece, 3,888; Italy, 16,683; Spain, 9,428; and Switzerland, 2,776. If denosumab was 
the selected treatment option for all patients, an estimated 38,690 SREs per year 
could be avoided, leading to 14,599 fewer hospitalisations, a reduction of 270,007 
inpatient days, and 155,213,984€ of savings in direct medical costs per year. The 
2014 costs saved by country were: Austria, 19,919,201€ ; Czech Republic, 4,095,737€ ; 
Germany, 36,895,464€ ; Greece, 18,504,154€ ; Italy, 24,529,334€ , Spain, 18,931,728€ and 
Switzerland, 31,338,666€ . cOnclusiOns: Denosumab can result in significant 
reductions in the number and length of inpatient stays of PC patients with BMs, 
leading to substantial savings of direct medical costs associated with the manage-
ment of SREs in each of the 7 European countries.
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Objectives: To estimate the total number of skeletal-related events (SREs) 
prevented, related hospital burden and direct medical expenditure when deno-
sumab is used instead of zoledronic acid for SRE prevention in seven European 
countries. MethOds: A model was developed combining country-specific breast 
cancer mortality data from the World Health Organization or from local regis-
tries, the proportion of metastatic breast cancer patients with bone metastases 
(BMs) at high risk of developing SREs from published literature, the prevalence 
